SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial and Strategy Officer of Veradermics, will host a corporate presentation at 3:10 p.m. ET Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 in Miami, FL Reid Waldman, M.D., Chief Executive Officer of Veradermi

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302' Study of VDPHL01 will be presented at the 2026 World Congress for Hair Research on May 30, 2026. The data to be presented includes positive topline results, shared by the company in April 2026, from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial (Study ‘302') evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. Veradermics believes th

Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that two E-posters will be presented at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE) beginning today in Nashville, Tennessee until May 17, 2026. The data to be presented include two comparative analyses of VDPHL01's Phase 2 male data results versus published data on the efficacy of existing minoxidil formulations. The first is a blinded, retrospective investigator global assessment in which nine independent dermatologists evaluated the perceived efficacy of VDPHL

Positive topline results from Phase 2/3 Study ‘302' position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years Upsized IPO and follow-on financing generated approximately $766.8 million in aggregate gross proceeds; pro forma cash expected to fund operations into 2030 through multiple Phase 3 readouts and potential launch Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate and clinical progress.

Veradermics, Incorporated ("Veradermics") (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the pricing of its upsized public offering of 3,843,790 shares of its common stock at a public offering price of $100.00 per share. All of the shares are being offered by Veradermics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $384.4 million. The offering is expected to close on May 1, 2026, subject to the satisfaction of customary closing conditions. In addition, Veraderm

Veradermics, Incorporated ("Veradermics") (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed public offering of 3,350,000 shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock) pursuant to a registration statement filed on Form S-1 with the Securities and Exchange Commission ("SEC"). All of the shares and pre-funded warrants are being offered by Veradermics. In addition, the underwriters are expected to have a 30-day option to purchase up to an additional 502,500 s

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6 Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patient

Conference call will take place on Monday, April 27, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302' clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males with mild-to-moderate pattern hair loss. Webcast Details: Time: Monday, April 27, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be available on the Events p

Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026 Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss Mark Neumann, seasoned biopharmaceutical commercial leader with more than 30 years of experience launching and scaling blockbuster therapies, appointed Chief Commercial and Strategy Officer Upsized IPO of $294.8 million closed in February 2026; pro forma cash, cash equivalents and marketable securities expected to fund planned operations into 2029, through multiple anticipated Phase 3 readouts and

Needham initiated coverage of Veradermics with a rating of Buy and set a new price target of $136.00

Cantor Fitzgerald initiated coverage of Veradermics with a rating of Overweight

Jefferies initiated coverage of Veradermics with a rating of Buy and set a new price target of $75.00

Citigroup initiated coverage of Veradermics with a rating of Buy and set a new price target of $85.00

Leerink Partners initiated coverage of Veradermics with a rating of Outperform and set a new price target of $75.00

4 - Veradermics, Inc (0001827635) (Issuer)

3 - Veradermics, Inc (0001827635) (Issuer)

4/A - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

3 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4/A - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

4 - Veradermics, Inc (0001827635) (Issuer)

SCHEDULE 13G/A - Veradermics, Inc (0001827635) (Subject)

D - Veradermics, Inc (0001827635) (Filer)

10-Q - Veradermics, Inc (0001827635) (Filer)

8-K - Veradermics, Inc (0001827635) (Filer)

SCHEDULE 13G - Veradermics, Inc (0001827635) (Subject)

SCHEDULE 13D/A - Veradermics, Inc (0001827635) (Subject)

SCHEDULE 13D - Veradermics, Inc (0001827635) (Subject)

8-K - Veradermics, Inc (0001827635) (Filer)

424B4 - Veradermics, Inc (0001827635) (Filer)

EFFECT - Veradermics, Inc (0001827635) (Filer)

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was achieved with VDPHL01 treatment as demonstrated by a mean increase in non-vellus target area hair count (TAHC) of 30.3 hairs/cm² (once daily dosing; p<0.0001) and 33.0 hairs/cm² (twice daily dosing; p<0.0001) versus 7.3 hairs/cm² for placebo at Month 6 Approximately 79.3% (QD) and 86.0% (BID) of patients reported any improvement in patient-reported outcomes (PRO) versus 35.6% of placebo patient

Conference call will take place on Monday, April 27, 2026 at 8:00 am ET Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 ‘302' clinical trial evaluating VDPHL01, a proprietary extended-release oral minoxidil tablet, in males with mild-to-moderate pattern hair loss. Webcast Details: Time: Monday, April 27, 2026 at 8:00 a.m. ET. Joining: The event and the accompanying slides will be available on the Events p